Dr. Daniel Sanford
Dr. Daniel Sanford is an expert in working with deadly diseases. Over his career, he’s led safety and efficacy studies for medical countermeasures against anthrax, melioidosis, botulism, bubonic plague and many other pathogens and biological warfare agents.
A Senior Research Scientist and Study Director at the Battelle Biomedical Research Center (BBRC), Dan conducts safety and efficacy studies required to bring new therapies and vaccines to market. His background includes extensive experience in bacterial pathogenesis, medical countermeasure discovery, infectious disease/containment lab research and animal model development. Prior to joining Battelle in 2006, he earned his B.A. in Biology from Elmira College and a Ph.D. in Molecular, Cellular and Developmental Biology from The Ohio State University.
Much of his work is conducted under the FDA Animal Rule; Dan was involved in the licensure of the very first product (Raxibacumab) for which the effectiveness was based solely on efficacy studies in animals. Since then, Dan has directed model development and efficacy studies designed to test vaccines and therapies againstBacillus anthracis, Botulinum Neurotoxin, Ricin, Burkholderia pseudomallei, Burkholderia mallei, and Yersinia pestis. His work has directly contributed to several new countermeasures now included in the Strategic National Stockpile for Biological Defense.
Dan is also involved in development of new animal models for disease. Most notably, he has played a significant role in the development of the Cynomolgus macaque inhalational therapeutic anthrax model, the Rhesus macaque inhalational botulinum neurotoxin model, the Rhesus macaque inhalational B. pseudomallei model, and the African green monkey B. mallei model.